SM-88
AssetAlso MPS, sirolimus, DNP-01, Racemetirosine
Metabolic-altering therapy component using modified dysfunctional tyrosine alongside MPS to disrupt cancer metabolism.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Oxidative stress and ROS signalling
- 1
- Indication
- 580
- Trials
- 1
- Developer
Indications
1Pancreatic cancer
Phase 2, Terminated, NCT03512756, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains4
- Owner and partners1
- Trials580
- Evidence for its targets4
- Competitors5
- Aging relevance2
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.